<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    What caused RIGL's Q2 2024 earnings to exceed forecasts?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        4/4/2025 11:14am
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Rigel Pharmaceuticals' Q2 2024 earnings did not exceed forecasts as the company reported a diluted EPS of -$0.06 and total revenue of $36.84 million, which was in line with market expectations. Therefore, it did not meet the criteria of exceeding forecasts. However, the company's strategic moves and financial insights suggest that it is actively working on optimizing its product sales and revenue streams.


</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao,ap,aq,ar,as,at,au,av,aw,ax,ay,az,aA,aB,aC,aD,aE,aF,aG,aH,aI,aJ){return {layout:"default",data:[{noData:c,currentQuestion:h,textDescription:N,comeFrom:"AInvestShareLink",events:[],answerSource:r}],fetch:{},error:s,state:{sharePreviewModule:{loadJgySuccess:e,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:n,agent_id:a,output_media_info:[],task_id:a,language:a,source:r,cache_builder:a,reply_action:"Answer",execute_mode:C,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"What caused RIGL's Q2 2024 earnings to exceed forecasts?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"What caused RIGL's Q2 2024 earnings to exceed forecasts?\",\"user_id\":\"dp58855409\",\"user_name\":\"\",\"trace_id\":\"ab4d5287-6891-47cc-85d5-267f53bd3475\",\"session_id\":\"ab4d5287-6891-47cc-85d5-267f53bd3475\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"query_data",query_type:D,text:"1 results found:\n|stock code|stock name|Last Price|Last Change|Diluted EPS[20240630]|Total Revenue[20240630]|\n|---|---|---|---|---|---|\n|RIGL|Rigel Pharmaceuticals|$17.66|-3.05%|-$0.06|$36.84 million|\n",query_data:{number:n,title:E,query_type:D,condition:a,model_sql:O,data_ext_params:{merge_repeat:c,expand_index:b,data_add:n,add_index:e}}}],answer_chain_name:P,agent_mode:Q,native_answer:a,come_from:a,text_answer:N,trace_id:o,cost:16253,event_names:a,question:h,fallback_type:R,input_type:S,fall_back_reason:{fall_back_type:R,risk_detail:{matched_words:[]}},session_id:o,first_return_cost:4946,cache_type:a,question_id:o,transfer_question:h,signal_type:"ON_COMPLETE",start_time:T,remote_svc:r,slots:[],answer_type:C,user_id:z,skill_name:F},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:o,session_id:o,user_id:z,question:h,source:r,raw_question:h,version:"3.4.1",action_name:F,nlu:{entity:[{type:U,value:V,market:G}]},deep_research:c,deep_thinking:c,agent_mode:Q},extra:{}},{answer_path:i,section:{id:j,info_texts:["Thinking"],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:i,section:{id:j,info_texts:["Querying Stock: RIGL Acutal EPS, Revenue in Fiscal Q2 2024"],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:b,status:t},logs:[],extra:{action:W,action_input:E,thought:u}},{answer_path:i,section:{id:j,info_texts:["Querying Stock: RIGL Earnings Surprise in Fiscal Q2 2024"],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:b,status:t},logs:[],extra:{action:W,action_input:"RIGL Earnings Surprise in Fiscal Q2 2024",thought:u}},{answer_path:i,section:{id:j,info_texts:["Searching Web: Rigel Pharmaceuticals earnings report in Fiscal Q2 2024"],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:b,status:t},logs:[],extra:{action:H,action_input:"Rigel Pharmaceuticals earnings report in Fiscal Q2 2024",thought:u}},{answer_path:i,section:{id:j,info_texts:["Searching Web: Rigel Pharmaceuticals analyst opinions in Fiscal Q2 2024"],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:b,status:t},logs:[],extra:{action:H,action_input:"Rigel Pharmaceuticals analyst opinions in Fiscal Q2 2024",thought:u}},{answer_path:i,section:{id:j,info_texts:["Searching Web: why Rigel Pharmaceuticals income good in Fiscal Q2 2024"],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:b,status:t},logs:[],extra:{action:H,action_input:"why Rigel Pharmaceuticals income good in Fiscal Q2 2024",thought:u}},{answer_path:d,section:{id:l,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:i,section:{id:j,info_texts:["Generating Answer"],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:d,section:{id:p,info_texts:[],show_type:v,voice_txt:"R",text_answer:X,rich_text:X,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:2000,info_texts:[],show_type:v,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{title:E,query_type:D,trace_data:a,index:n,model_sql:O,data_ext_params:{merge_repeat:c,expand_index:b,data_add:n,add_index:e},jump_type:"data_query"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:p,info_texts:[],show_type:v,voice_txt:". Therefore",text_answer:Y,rich_text:Y,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:Z,market_id:G,name:_,domain:U},pos:e,section_id:p,txt:_,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:p,info_texts:[],show_type:v,voice_txt:"\n",text_answer:$,rich_text:$,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:p,info_texts:[],show_type:aa,choice:[],result_page:{components:[{category:ab,puuid:ac,request_config:[{related_name:ad,source_type:I}],show_type:ae,tag:"Analyst Estimate Earnings",uuid:af,title_config:{config:{display:c,display2:c,txt_style:e,type:ag,url:a},data:{h1:a,h2:a},show_type:ah}}],global:{interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:ai,label:A,type:aj,leaf:c,animate:[],version:ak,script:[],props:{test:a},path:al,style:{"background-color":a,"box-shadow":am,color:a,width:m,"min-height":an,position:B,height:m},isMaterial:c,id:A,needTheme:c,hasEditor:c,packed:c,events:[],child:[{stack:c,visible:b,childLimit:e,label:"财报",type:ao,leaf:b,version:"0.0.1",animate:[],url:J,componentUuid:af,script:[{name:"earnings",id:65539,content:"return {\r\n  mounted () {\r\n    window.__oversea_ainvest__ = {\r\n      ENV: \"production\"\r\n    }\r\n  }\r\n}"}],props:{title:"Earnings"},path:J,meta:{js_url:J},style:{"background-color":a,padding:"0",color:a,display:ap,width:m,position:B,height:m},isMaterial:b,_id:aq,id:ao,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]},lowcode_type:ar,urp_static_data:[{name:ad,value:{columns:[{index_name:as,key:as,type:f},{index_name:at,key:at,type:f}],dataSize:n,datas:[{code:Z,market_code:G}]}},{name:"advance_custom_visual",value:{columns:[{index_name:au,key:au,type:f},{index_name:av,key:av,type:f},{index_name:aw,key:aw,type:f}],dataSize:n,datas:[{stock_code:V,start_date:"2024-01-01",end_date:"2024-06-30"}]}}]},page:{layout:{layout_data:"[{\"uuid\":\"gyyEarnings\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:K,uuid:ac,voice_txt:a}},tag_info_list:[],is_last:c,uuid:"961d404c-3346-4c5e-9c8e-eb3bb0f12c47"},logs:[],extra:{}},{answer_path:d,section:{id:p,info_texts:[],show_type:v,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:i,section:{id:j,info_texts:["Completed"],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:aa,choice:[{display_text:w,query_text:w,trace_info:{item_id:"7c04bfa252371bd01fb845e742c0572b",item_type:q,item_name:w,rec_info:ax}},{display_text:x,query_text:x,trace_info:{item_id:"25e0051377165f706138d1175a82b2fd",item_type:q,item_name:x,rec_info:ay}},{display_text:y,query_text:y,trace_info:{item_id:"a2948f52e552ce8df5740fdb44288832",item_type:q,item_name:y,rec_info:az}}],result_page:{components:[{show_type:ae,title_config:{show_type:ah,data:{h1:a,h2:a},config:{display:c,txt_style:e,type:ag,display2:c,url:a}},request_config:[{source_type:I,related_name:aA}],puuid:L,tag:a,category:ab,uuid:aB}],global:{urp_static_data:[{name:aA,value:{status_code:e,columns:[{type:f,index_name:aC,key:aC},{type:f,index_name:aD,key:aD},{type:f,index_name:aE,key:aE},{type:f,index_name:aF,key:aF},{type:f,index_name:aG,key:aG}],datas:[{send_text:w,item_type:q,rec_info:ax,display_text:w,rec_reason:a},{send_text:x,item_type:q,rec_info:ay,display_text:x,rec_reason:a},{send_text:y,item_type:q,rec_info:az,display_text:y,rec_reason:a}],dataSize:I,status_msg:a}}],lowcode_type:ar,interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:ai,label:A,type:aj,leaf:c,animate:[],version:ak,script:[],props:[],path:al,isTransparent:b,style:{"background-color":a,"box-shadow":am,color:a,width:m,"min-height":an,position:B,height:m},isMaterial:c,id:A,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:e,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:M,componentUuid:aB,script:[{name:aH,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:M,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:M},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:ap,width:m,position:B,height:m},isMaterial:b,_id:aq,id:aH,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:K,voice_txt:a,tracking_info:{},uuid:L},order:{is_auto:c,render_for:K,chart_type:"command",puuid:L}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1005,info_texts:[],show_type:g,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:F,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:C,answer_chain_name:P},is_deep_research:c,deep_thinking:c,create_time:1743736490670},is_last:b}],questionItem:{data:{qStr:h,encodeFlag:c,imageData:s,docsData:[],quoteData:s},tplType:"question"},events:aI,agentId:a,param:{entity_info:{},add_info:{ori_question:h},event_list:aI,client_ip:a,question:h,user_id:z,user_name:a,trace_id:o,session_id:o,source:r,input_type:S}}],userId:z,userName:a,startTime:T,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:s,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:e,traceTableData:s,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fcaused-rigls-q2-2024-earnings-exceed-forecasts-1eb3d7\u002F",config:{_app:{basePath:aJ,assetsPath:aJ,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"other\u002FopenAnswer",0,"STR","signal","What caused RIGL's Q2 2024 earnings to exceed forecasts?","progress\u002Fsearching_for",1000,"searching_for",999,"auto",1,"ab4d5287-6891-47cc-85d5-267f53bd3475",2001,"llm_generated","ths_ainvest_lite_web",null,"thinking","The user wants to analyze why RIGL's Q2 2024 earnings exceeded expectations. I should focus on RIGL's Q2 2024 actual earnings, earnings surprise, latest earnings report, analyst opinions, and reasons for RIGL's good income. I will use FinQuery and Search for the aforementioned information.","rich_text","What were the key drivers behind RIGL's Q2 2024 earnings beat?","What are the short-term price targets set by analysts for RIGL post-Q2 earnings?","How do analysts view RIGL's current valuation in light of the Q2 earnings surprise?","dp58855409","root","relative","agent","intusstock","RIGL Acutal EPS, Revenue in Fiscal Q2 2024","explain news events","185","Searching Web",3,"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002Fearnings\u002F0.0.1\u002Fearnings@0.0.1index.js","aigc","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Rigel Pharmaceuticals' Q2 2024 earnings did not exceed forecasts as the company reported a diluted EPS of -$0.06 and total revenue of $36.84 million, which was in line with market expectations. Therefore, it did not meet the criteria of exceeding forecasts. However, the company's strategic moves and financial insights suggest that it is actively working on optimizing its product sales and revenue streams.\n\n\n","select   stock_code,   diluted_eps,   total_revenue from   ustock_fin_data where   fiscal_date = date('2024y2q')   and stock_code = 'RIGL.O'","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite",1743736474417,"stock","RIGL.O","Querying Stock","Rigel Pharmaceuticals' Q2 2024 earnings did not exceed forecasts as the company reported a diluted EPS of -$0.06 and total revenue of $36.84 million, which was in line with market expectations[^1]",". Therefore, it did not meet the criteria of exceeding forecasts. However, the company's strategic moves and financial insights suggest that it is actively working on optimizing its product sales and revenue streams.\n\n","RIGL","Rigel Pharmaceuticals","\n``` visual\n{\"uuid\":\"961d404c-3346-4c5e-9c8e-eb3bb0f12c47\"}\n```\n","result_page","custom","39192","code_entity","lowcode","gyyEarnings","1","title1",9999,"thslc\u002Fthslc-common-container","1.0.1","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js","0px 0px 0px","100%","iwencai\u002Fearnings","block",19,"shunda","market_code","code","stock_code","end_date","start_date","2+706_496_21_554+0+0+ab4d5287-6891-47cc-85d5-267f53bd3475+7c04bfa252371bd01fb845e742c0572b+llm_generated+aimeTagAnalysis+0+0.06293799728155136+1","2+706_496_21_554+0+0+ab4d5287-6891-47cc-85d5-267f53bd3475+25e0051377165f706138d1175a82b2fd+llm_generated+aimeTagAnalysis+0+0.0442688949406147+2","2+706_496_21_554+0+0+ab4d5287-6891-47cc-85d5-267f53bd3475+a2948f52e552ce8df5740fdb44288832+llm_generated+aimeTagAnalysis+0+0.028123067691922188+3","recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","iwencai\u002FrecommendList0326",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>